Pulse Biosciences advances NANOPULSE-AF pivotal study enrollment
I'm LongbridgeAI, I can summarize articles.Pulse Biosciences (PLSE) announced that its NANOPULSE-AF pivotal clinical study has surpassed the enrollment midpoint for patients with recurrent, drug-resistant paroxysmal atrial fibrillation. The multicenter trial evaluates the nPulse Cardiac Catheter System, with investigators citing intuitive workflow and safety as drivers for rapid enrollment. This milestone strengthens Pulse's position in the AF ablation market. Analyst ratings vary, with some recommending a Buy at $35.00, while TipRanks' AI suggests Neutral due to weak financials despite positive clinical momentum.
Pulse Biosciences ( (PLSE) ) has issued an update.
On July 29, 2026, Pulse Biosciences reported that its NANOPULSE-AF pivotal clinical study, which began in April 2026, has surpassed the enrollment midpoint in patients with recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The prospective, multicenter investigation is evaluating the nPulse Cardiac Catheter System across as many as 30 sites, including locations outside the U.S., reflecting broad clinical interest in the firm’s nano-PFA technology.
Clinical investigators highlighted the system’s intuitive workflow, minimal learning curve and apparent safety profile as key drivers of rapid patient enrollment, underscoring enthusiasm for its potential durability in pulmonary vein isolation. The swift progress toward completing this IDE study marks a significant operational milestone for Pulse Biosciences and may strengthen its positioning in the competitive AF ablation market, with stakeholders awaiting full pivotal data to assess commercial and clinical implications.
The most recent analyst rating on (PLSE) stock is a Buy
with a $35.00 price target.
To see the full list of analyst forecasts on Pulse Biosciences stock,
see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held back primarily by weak financial performance (large losses and persistent cash burn despite modest leverage). Offsetting this are strong technical momentum and a generally positive earnings-call narrative centered on compelling clinical results and accelerated trial/regulatory milestones, supported by stated financing flexibility. Valuation provides limited support given negative earnings and no dividend.
To see Spark’s full report on PLSE stock,
click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a bioelectric medicine company developing proprietary nPulse nanosecond Pulsed Field Ablation technology designed to non-thermally clear targeted cells while sparing adjacent tissue. The company is focused on applications in atrial fibrillation and select additional markets where its cardiac catheter systems and related platforms could materially improve outcomes for patients and providers.
Its portfolio includes the nPulse Cardiac Catheter System and other branded technologies such as Vybrance and CellFX, which leverage nano-PFA to deliver precise ablations. Pulse Biosciences aims to position its nPulse platform as a next-generation ablation modality within electrophysiology, aligning with the trend toward ablation as a first-line therapy for atrial fibrillation in key global healthcare markets.
Average Trading Volume: 363,391
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.27B
Learn more about PLSE stock on TipRanks’ Stock Analysis page.